Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q6ZMJ4
UPID:
IL34_HUMAN
Alternative names:
-
Alternative UPACC:
Q6ZMJ4; B2RC28; B2Z4A8; B2ZC70; Q8N6L2
Background:
Interleukin-34 (IL-34) is a pivotal cytokine that orchestrates the proliferation, survival, and differentiation of monocytes and macrophages. It is instrumental in the release of pro-inflammatory chemokines, playing a crucial role in innate immunity and inflammatory processes. Furthermore, IL-34 is vital in regulating osteoclast proliferation and differentiation, as well as bone resorption, through signaling via CSF1R and subsequent phosphorylation of MAPK1/ERK2 and MAPK3/ERK1.
Therapeutic significance:
Understanding the role of Interleukin-34 could open doors to potential therapeutic strategies, especially in the context of inflammatory diseases and disorders related to bone resorption.